In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Aerie Pharma (NASDAQ: AERI), with a price target of $77. The company’s shares closed yesterday at $49.95.
Yang commented:
“We remain confident in the management team as the Rhopressa launch progresses and reiterate our Buy rating on the stock.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 20.2% and a 50.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
Currently, the analyst consensus on Aerie Pharma is Strong Buy and the average price target is $81.75, representing a 63.7% upside.
In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $86 price target.
See today’s analyst top recommended stocks >>
Based on Aerie Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $40.7 million. In comparison, last year the company had a GAAP net loss of $25.79 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company’s product candidates are Rhopressa and Roclatan.
